Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:21:53.050Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:21:53.050Z.
Quote observation: 2026-10-06T14:20:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
FORWARD PE RATIO
N/A
Freenome, Inc.
Market Cap
$133.86M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Freenome, Inc. (FRNM) | $133.86M | N/A |
| LifeMD, Inc. (LFMD)vs › | $134.69M | N/A |
| KORU Medical Systems, Inc. (KRMD)vs › | $137.57M | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $138.28M | 6.89 |
| AirSculpt Technologies, Inc. (AIRS)vs › | $138.62M | N/A |
| Alpha Cognition Inc (ACOG)vs › | $141.33M | N/A |
| Health Catalyst, Inc. (HCAT)vs › | $130.42M | N/A |
| LifeMD, Inc. (LFMDP)vs › | $142.72M | N/A |
| Immuneering Corporation (IMRX)vs › | $144.85M | N/A |
| Entera Bio Ltd. (ENTX)vs › | $126.43M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
